Revenues (Tables)

12 Months Ended

Dec. 31, 2019

Revenues Abstract

Schedule of disaggregation of revenue from contracts with customers

	Year Ended December 31,
Pharmaceutical Product	2019		2018
Venlafaxine ER	$	75,601	$	66,039
Methylphenidate ER		73,205		129,469
Lorzone		15,004		17,172
Divigel		26,794		23,314
OB Complete		9,851		10,510
Other		35,017		14,894
Net product sales		235,472		261,398
Royalty revenue		3,641		1,959
License and contract revenue		918		344
Total revenues	$	240,031	$	263,701